GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 135,400
-1,800 (-1.31%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| Manufacturing and Sales of Pharmaceuticals, etc. | 1,580.98B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Manufacturing and Sales of Pharmaceuticals, etc. Growth | 9.72% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnosis and Analysis of Specimens, etc. | 200.12B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnosis and Analysis of Specimens, etc. Growth | -6.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Adjustment, etc. | -117.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Adjustment, etc. Growth | 152.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 16.06B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -13.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| South Korea | 1,416.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | 1.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas | 380.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas Growth | 39.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Adjustment | -117.27B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consolidation Adjustment Growth | 152.23% |
Log In |
Log In |
Log In |
Log In | Upgrade
|